Recent advances in drug delivery and formulation最新文献

{"title":"Integrating Artificial Intelligence with Liposomal Nanocarriers for Advanced Drug Delivery.","authors":"Pravin Kumar, Sunny Bhardwaj, Ajay Kumar, Tarun Kumar Sharma, Dev Raj Sharma, Mahendra Singh Ashawat, Ankit Sharma","doi":"10.2174/0126673878475998260827065237","DOIUrl":"https://doi.org/10.2174/0126673878475998260827065237","url":null,"abstract":"<p><strong>Introduction: </strong>Liposomal drug delivery systems have achieved notable clinical success; however, their wider translation is often limited by complex formulation variables, unpredictable process behavior, and scalability challenges. Traditional trial-and-error optimization strategies struggle to address the nonlinear relationships that govern liposome quality, performance, and reproducibility. Recent advances in Artificial Intelligence (AI) and Machine Learning (ML) offer promising alternatives by enabling data-driven formulation design and process understanding.</p><p><strong>Methods: </strong>This review critically evaluates peer-reviewed studies published over the past decade that report the application of AI and ML in liposomal formulation development, microfluidic manufacturing, quality attribute prediction, and therapeutic performance assessment. Emphasis was placed on studies integrating computational models with experimental and advanced manufacturing workflows.</p><p><strong>Results: </strong>The reviewed literature demonstrates that AI-based models, including neural networks, deep learning architectures, and ensemble approaches, consistently outperform conventional statistical tools in predicting critical quality attributes such as particle size, polydispersity index, drug entrapment efficiency, stability, and release behavior. Integration of AI with microfluidic platforms further enables real-time process monitoring, improved reproducibility, and continuous manufacturing.</p><p><strong>Discussion: </strong>These findings highlight AI as a powerful framework for capturing complex relationships among formulation, process, and performance. Beyond optimization, AI facilitates deeper mechanistic understanding and supports predictive control strategies for liposomal systems.</p><p><strong>Conclusion: </strong>AI-integrated approaches represent a paradigm shift in liposome development, offering accelerated formulation design, enhanced scalability, and improved prospects for reliable clinical translation.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Innovations in Nanoemulsion and Nanoemulgel-Based Topical Drug Delivery Systems: Formulation, Characterization, and Clinical Translation.","authors":"Mohd Zafar, Prevesh Kumar, Diksha, Navneet Verma","doi":"10.2174/0126673878460827260827113408","DOIUrl":"https://doi.org/10.2174/0126673878460827260827113408","url":null,"abstract":"<p><p>Nanoemulgel technology has been widely recognized for its potential to design efficient topical dosage forms by leveraging the solubilizing properties of nanoemulsions and the advantageous application properties of gels. This synergy is highly advantageous for countering the drawbacks of conventional topical formulations, including impaired delivery of lipophilic and poorly water-soluble drugs. In this review, recent developments in nanoemulgel formulations are highlighted, with particular focus on how associated formulation variables, preparation techniques, and key physicochemical factors affect therapeutic efficacy. Rather than delving into basic details, features such as particle size, surface charge, stability, and drug release patterns in a formulation are explained in terms of formulation quality and therapeutic usefulness. The therapeutic application of nanoemulgels in dermatological, anti-inflammatory, antimicrobial, and cosmetic applications is exemplified to clarify improvements in therapeutic efficacy, decreased systemic toxicity, and increased patient acceptability. Current trends in nano-emulgels, including targeted delivery designs, personalized formulation designs, and biocompatible excipients, are mentioned briefly. From the present evidence, the validity and future potential of nano-Emulgel technology in general, and its clinically significant application in designing efficient topical drug delivery, are evident.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanostructured Cubosomal Gels for Targeted Drug Delivery in Rheumatoid Arthritis: Advances in Nanomedicine and Therapeutic Nanotechnology.","authors":"Ashok Thulluru, Chandraprabhu Jangme, Vrushabh Patil","doi":"10.2174/0126673878470708260902071103","DOIUrl":"https://doi.org/10.2174/0126673878470708260902071103","url":null,"abstract":"<p><p>Introduction/ Objective: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints, leading to joint destruction and systemic complications. Existing therapies, such as Disease-Modifying Antirheumatic Drugs (DMARDs) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), are typically associated with low efficiency, systemic side effects, and poor patient compliance.</p><p><strong>Methods: </strong>A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Web of Science to identify relevant studies published between 2005 and 2025. The search employed the keywords \"rheumatoid arthritis,\" \"cubosomes,\" \"cubosomal gel,\" \"nanocarriers,\" and \"targeted drug delivery\" with Boolean operators (AND/OR). English-language studies focusing on cubosome-based drug delivery for rheumatoid arthritis were included, while non-English publications, duplicates, and unrelated studies were excluded. The selected literature was qualitatively synthesized to summarize current advances and therapeutic potential.</p><p><strong>Results: </strong>Preclinical research demonstrates that cubosomal gels enhance Pharmacodynamic effects, improve drug retention in inflamed joints, and reduce systemic toxicity. Such systems show improved bioavailability and therapeutic action compared to traditional therapies. Nonetheless, issues such as scale-up manufacturing, stability, and regulatory acceptance remain.</p><p><strong>Discussions: </strong>Cubosomal gels would be an effective platform for safer, more effective, and personalized RA therapies. New studies are advised on stimuli-responsive systems and multifunctional targeting to maximize clinical responses and translate them into patient care.</p><p><strong>Conclusion: </strong>Nanocarrier-based drug delivery systems offer enhanced targeted delivery and controlled release. Cubosomes, lipid-based nanostructures with bicontinuous cubic phases, effectively encapsulate both hydrophilic and hydrophobic drugs. This study demonstrates that cubosomes significantly improve topical RA treatment when incorporated into gel formulations, enhancing skin penetration, bioadhesion, and localized drug delivery. These findings have important clinical implications, suggesting cubosomes may reduce systemic side effects while maximizing therapeutic efficacy at diseased sites.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioengineered Amphiphilic Chitosan Nanocarriers for Improved Oral Absorption of Poorly Soluble Antihypertensive Agents.","authors":"Gouri Jamuar, Shikha Baghel Chauhan, Chirag Jain, Indu Singh","doi":"10.2174/0126673878472330260824142811","DOIUrl":"https://doi.org/10.2174/0126673878472330260824142811","url":null,"abstract":"<p><p>The clinical efficacy of many antihypertensive medications is constrained by their poor water solubility, low membrane permeability, significant first-pass metabolism, and uncertain oral bioavailability, even though hypertension is still a major worldwide health concern. For BCS Class II and IV medications like telmisartan, amlodipine, nifedipine, and carvedilol, these restrictions are especially important and call for creative delivery methods. Because of their unique dual hydrophilic-hydrophobic structure, amphiphilic chitosan derivatives have emerged as adaptable nanocarriers that may overcome these limitations. Chitosan can self-assemble into micelles, nanoparticles, nanoemulsions, and hybrid systems, with high encapsulation efficiency for lipophilic drugs when chemically modified with alkyl chains, fatty acids, bile acids, sterols, or synthetic polymer segments. By keeping medications in an amorphous, molecularly dispersed state and providing protection against gastrointestinal degradation, these nanostructures improve solubility. In addition to increasing solubility, amphiphilic chitosan improves drug permeation and systemic absorption by providing strong mucoadhesion, extended intestinal residence, and temporary modulation of tight junctions. Combined oral delivery with these carriers often results in a 2- to 3- fold increase in bioavailability and extended antihypertensive action in preclinical studies. Moreover, amphiphilic chitosan systems can provide sustained and extended release, with reduced peak-trough fluctuations and enhanced therapeutic stability. Their natural origin, biodegradability, acceptable safety profile, and regulatory acceptability strengthen their translation potential. This review carefully scrutinizes the chemistry and self-assembly processes, formulation strategies, pharmacokinetic advantages, safety-related issues, and potential uses of amphiphilic chitosan-based nanocarriers. All things considered, these technologies represent an interesting emerging delivery approach that may improve the oral bioavailability and therapeutic efficacy of poorly soluble antihypertensive drugs.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Progress in Chitosan Nanoparticles for the Oral Delivery of Proteins and Peptides: Strategies to Improve Bioavailability.","authors":"Varun, Navdeep Singh, Md Moidul Islam, Moidul Islam Judder, Himanshu Jain, Md Nasiruddin Khan","doi":"10.2174/0126673878485851260825075213","DOIUrl":"https://doi.org/10.2174/0126673878485851260825075213","url":null,"abstract":"<p><strong>Introduction: </strong>The oral delivery of proteins or peptides remains a significant challenge due to enzymatic degradation in the gastrointestinal tract, low epithelial permeability, and low bioavailability. Chitosan nanoparticles (CNPs) have been developed to overcome these disadvantages due to their biodegradability, biocompatibility, mucoadhesiveness, and ability to transiently disrupt epithelial tight junctions, thereby improving drug absorption.</p><p><strong>Methods: </strong>This review summarizes the latest literature from 2020 to 2025 on the physicochemical properties, formulations, preclinical and clinical studies, and regulatory issues related to CNP delivery systems. To ensure access to reliable peer-reviewed articles and scholarly sources, relevant studies were obtained from reputable scientific databases, including PubMed, ScienceDirect, Scopus, and Google Scholar.</p><p><strong>Results: </strong>CNPs can effectively enhance the stability, absorption, and therapeutic efficacy of biopharmaceuticals. A number of studies reported encapsulation efficiencies as high as 90% and significant improvements in the oral bioavailability of insulin, anticancer drugs, and oral vaccines. Both in vitro and in vivo studies showed consistently better pharmacokinetic properties, increased mucosal permeation, and better therapeutic efficacy. Further, toxicological assessments showed good safety profiles at therapeutic doses.</p><p><strong>Discussion: </strong>While there is significant potential, problems with scalability, stability, and regulatory standardization remain unresolved. New formulation technologies and individualised 'nanomedicine' could help to address these limitations.</p><p><strong>Conclusion: </strong>Overall, CNPs are a transformative nanoplatform with great potential to improve the delivery of biopharmaceuticals via the oral route, enhancing patient adherence and therapeutic efficacy.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of the Human Gut Microbiome on Xenobiotic Metabolism and Pharmacokinetic Outcomes: From Bench to Bedside.","authors":"Hiral Vadgama, Parixit Prajapati, Ashish Patel, Chandni Chandarana","doi":"10.2174/0126673878476320260813063101","DOIUrl":"https://doi.org/10.2174/0126673878476320260813063101","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacomicrobiomics is the interdisciplinary area of research arising from studies demonstrating that the microbiota in the human colon dynamically regulates the metabolism of many medications. This review paper discusses how this microbiota may explain some of the variability observed in patient responses to medication, and describes the role of gut-associated microbial communities in the metabolism, effectiveness, and safety of drugs.</p><p><strong>Methods: </strong>Using important scientific databases, a thorough and methodical review of the literature was carried out with an emphasis on preclinical and clinical research examining microbiota-drug interactions. Microbial biotransformation pathways, enzyme-mediated metabolism (such as β- glucuronidases, azoreductases, and reductases), and the impact of dysbiosis, probiotics, and antibiotics on drug pharmacokinetics were important topics. New computational and microbiome-based prediction methods were also assessed.</p><p><strong>Results: </strong>The gut microbiota has a substantial impact on drug bioavailability, metabolism, enterohepatic recirculation, and toxicity, according to mounting data. Anticancer, cardiovascular, and antidiabetic medications are among the many therapeutic classes whose pharmacokinetics are changed by microbial enzymatic activity. Clinically significant variability in drug response is caused by microbiome disruptions, such as dysbiosis brought on by antibiotics. Promising methods for forecasting microbiota-driven pharmacokinetic variations are provided by recent developments in pharmacomicrobiomic profiling and in silico modelling.</p><p><strong>Discussion: </strong>These results highlight the gut microbiota as an important but little-known factor influencing pharmacokinetic behaviour and treatment effectiveness. Combining pharmacogenomic frameworks with microbiome data could improve tailored medication treatment. However, issues like interindividual microbial diversity, a lack of analytical method standardisation, and a lack of adequate translational models continue to be major obstacles.</p><p><strong>Conclusion: </strong>Drug metabolism and pharmacokinetic variability are significantly influenced by the gut microbiota-drug axis. Optimising therapeutic outcomes, reducing side effects, and advancing precision pharmacotherapy are all possible with the integration of microbiome-based insights into clinical decision-making and drug development.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148908472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Therapeutic Advances and Emerging Repurposing Strategies of Posaconazole: A Comprehensive Review.","authors":"Honey Goel, Priyanka Gupta, Mohammad Ubaid, Namrata Gautam, Anjali Singh, Sonal Setya, Sushama Talegaonkar","doi":"10.2174/0126673878488583260810061451","DOIUrl":"https://doi.org/10.2174/0126673878488583260810061451","url":null,"abstract":"<p><p>Globally, fungal diseases exert a considerable toll on human health, exhibiting wideranging epidemiological patterns across geographic locales. In the post-COVID era, the prevalence and risk of fungal infections have grown at an unprecedented pace, posing a colossal challenge to people with impaired immune systems owing to indiscriminate use of immunosuppressants and anti-fungal agents. In recent times, posaconazole (PCZ), a triazole with broad-spectrum activity, has emerged as a promising therapeutic option for the efficacious management of invasive fungal infections caused by Candida spp., Aspergillus spp., and Zygomycetes, with superior protection against endemic fungi such as Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides immitis. PCZ (commercially available as Noxafil® suspension at a dose of 40 mg/ml and delayed release tablet with a daily dose of 300-600 mg) was one of the front-line therapies approved by the USFDA in 2006 for the prophylactic treatment of COVID-associated pulmonary aspergillosis or mucormycosis, especially among critically immunocompromised patients undergoing mechanical ventilation and high-dose steroid treatment for progressive pulmonary disease. In clinical settings, existing PCZ formulations (tablets/suspensions) have achieved suboptimal peak plasma drug concentrations in critically ill patients owing to poor bioavailability. Therefore, the scientific community is striving to design and fabricate novel PCZ formulations with improved pharmacokinetic performance and therapeutic efficacy compared to existing dosage forms. This comprehensive review study aims to elucidate the mechanistic corroborations on therapeutic efficacy of PCZ and its resistance, considerations in the formulation and optimization (such as drug-drug interactions, variable absorption, and potential adverse effects such as hepatotoxicity and gastrointestinal disturbances) necessitate vigilant monitoring and dose adjustments by investigating marketed products, clinical trials, patented formulations, for its enhanced pharmacokinetic performance and continued surveillance of PCZ in clinical practice.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Lyophilized Ebastine-Loaded Novasome Tablets: Comprehensive Physicochemical Characterization and In Vitro/In Vivo Release Evaluation.","authors":"Salam ShantaTaher, Hussein J Alhazza, Hussein K Alkufi, Asmaa M Rashid, Nawal A Rajab, Abbas K Okab","doi":"10.2174/0126673878518331260819100058","DOIUrl":"https://doi.org/10.2174/0126673878518331260819100058","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Ebastine, a second-generation H1 antihistamine, exhibits poor aqueous solubility and consequently low oral bioavailability, limiting its clinical therapeutic efficacy. Novasome is an advanced vesicular nanocarrier system that offers a promising approach to enhance the solubility and dissolution behavior of a poorly water solubility drug. Therefore, this study aimed to develop, optimize, and characterize ebastine-loaded novasomes and to compress them into tablets to enhance drug solubility, dissolution, and oral bioavailability.</p><p><strong>Methods: </strong>Ebastine-loaded novasomes were prepared and optimized, then converted into lyophilized tablets using a suitable cryoprotectant. The optimized formulation was characterized for Particle Size (PS), Polydispersity Index (PDI), Zeta Potential (ZP), and Entrapment Efficiency (EE). Solidstate properties were assessed via Differential Scanning Calorimetry (DSC) and X-Ray Diffraction (XRD), while drug-excipient compatibility was evaluated using Fourier-Transform Infrared Spectroscopy (FTIR). In-vitro release studies were performed under stimulated physiological conditions, and in-vivo pharmacokinetic evaluation was conducted in Wistar rats.</p><p><strong>Results: </strong>The selected ebastine-loaded novasome exhibited a mean particle size of 189.9nm, a polydispersity index of 0.31, and an entrapment efficiency of 86.19%. In-vitro release exceeded 90% over 12 hours, significantly surpassing the dissolution profile of pure ebastine. DSC and XRD analyses confirmed amorphization of the drug within the Novasomal matrix, while FTIR revealed no evidence of drug-excipient compatibility. In-vivo studies demonstrated a 493.88% increase in relative oral bioavailability compared to free drug suspension (p < 0.05).</p><p><strong>Discussion: </strong>The enhanced dissolution and bioavailability are attributable to drug amorphization, high surface area to volume ratio of the nanovesicles, and protective entrapment of ebastine within the bilayer structure, which together improved gastrointestinal solubilization and oral bioavailability.</p><p><strong>Conclusion: </strong>The lyophilized Ebastine-loaded novasome tablet constitutes a stable, effective, and pharmacokinetically superior oral dosage form, offering significant potential for enhance the oral bioavailability of poorly water-soluble drugs.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PEGylated Liposomal Nanocarriers in Cancer Therapy: Emerging Strategies and Clinical Prospects.","authors":"Ashish Kumar, Md Moidul Islam, Moidul Islam Judder, Himanshu Jain, Nitish Kumar","doi":"10.2174/0126673878471991260809200127","DOIUrl":"https://doi.org/10.2174/0126673878471991260809200127","url":null,"abstract":"<p><strong>Introduction: </strong>Nanomedicine has changed the course of oncology through drug-delivery systems that improve efficacy while reducing systemic toxicity. PEGylated liposomes have specifically revolutionized cancer treatment by enhancing pharmacokinetics, stability, and tumor-selective deposition via the enhanced permeability and retention (EPR) effect.</p><p><strong>Methods: </strong>The keywords applied in the literature review included PEGylated liposomes, nanomedicine, and drug delivery in cancer, which were used to identify relevant studies. Data were gathered from credible databases in PubMed, ScienceDirect, and Google Scholar, with emphasis on peerreviewed, most recent publications in English.</p><p><strong>Results: </strong>PEGylation has been shown to extend the circulatory lifetime, enhance drug deposition in tumors, and minimize off-target toxicity. Clinical reports indicated that PEGylated preparations were superior and better tolerated than standard chemotherapy, particularly in breast, ovarian cancer, and pancreatic malignancies. New therapeutic potential can be unlocked through gene delivery, RNA-based therapies, and combination regimens.</p><p><strong>Discussion: </strong>Clinical success has been achieved, but shortcomings exist, such as the accelerated blood clearance (ABC) effect, PEG immunogenicity, and drug accumulation heterogeneity that are due to EPR. To address those challenges, more effective design solutions should be employed, including stimuli-responsive liposomes and patient-tailored methods.</p><p><strong>Conclusion: </strong>PEGylated liposomes are a pharmaceutically established and maturing nanomedicine technology in oncology. Their further advancement toward multifunctional, personalized, and immunologically safer designs promises to deliver cancer therapeutics.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanocarrier-Delivered Polyphenols: A Novel Strategy for Gut Microbiota Modulation and Cognitive Health Enhancement.","authors":"Shipra Sharma, Parul Gupta, Utkarshini Singh, Prashant Upadhyay, Reetika Rawat, Suman Sharma, Anjani Kumar Dwivedi, Ankit Chaurasia","doi":"10.2174/0126673878437375260730074233","DOIUrl":"https://doi.org/10.2174/0126673878437375260730074233","url":null,"abstract":"<p><strong>Introduction: </strong>The gut microbiota is a matrix ecosystem vital for the maintenance of host metabolic, immune, and neurological health. Disruption of this balance, known as gut dysbiosis, is associated with numerous diseases, including diabetes and neurological disorders. Dietary polyphenols, particularly flavonols like quercetin, have shown potential in restoring microbial balance. However, their poor solubility and low bioavailability limit therapeutic outcomes.</p><p><strong>Methods: </strong>This review evaluates the role of dietary polyphenols in modulating gut microbiota and explores nanocarrier-based approaches to enhance their stability and targeted delivery. Literature from recent preclinical and clinical studies was analysed to highlight the interaction between polyphenols and gut microbes with the advancement of nano-delivery systems.</p><p><strong>Results: </strong>Polyphenols influence gut microbiota by promoting beneficial production. Nanocarriers such as liposomes and polymeric nanoparticles improve the bioavailability and colon-targeted release of polyphenols, leading to improved gut axis function and impacting mood, cognition, and neuroprotection.</p><p><strong>Discussion: </strong>Nanocarrier systems offer an innovative solution to overcome the limitations of conventional polyphenol delivery. Enhanced colonic release allows direct modulation of gut microbiota and improved systemic outcomes, particularly in metabolic and neurological conditions.</p><p><strong>Conclusion: </strong>Nanocarrier-based delivery of polyphenols holds promise in managing gut dysbiosis and related disorders by improving bioavailability and targeting microbial balance. This approach supports the development of microbiota-focused dietary therapeutics.</p>","PeriodicalId":94352,"journal":{"name":"Recent advances in drug delivery and formulation","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}